Silencing Gal‐3 in RCC cells decreased CSC formation, drug resistance and CXCR2, while CXCR2 overexpression in Gal‐3‐knockdown cells restored the tumorigenesis ability. This evidence concerns the gene CXCR2 and renal cell adenocarcinoma.